Evidence map›Paper›PMID 40354010›Full record

Trial reportAdvances in therapy2025

Anlotinib Plus Docetaxel is Promising in Advanced NSCLC Progressing on First-Line Immunotherapy: A Pooled Analysis of Two Randomized Trials.

Xingxiang Pu, Jiawei Shou, Zemin Xiao, Jun Chen, Maoliang Xiao, Qunyi Guo, Zhongxia Ma, Wei Hong, Qianzhi Wang, Yonghui Wang and 6 more

2 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03624309 phase2unknown statusnot on this map

Anlotinib Plus Docetaxel Versus Docetaxel for Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer After Disease Progression on Platinum-based Therapy : a Multicentre, Double-blind, Randomised Explorative Trial

TypeinterventionalSponsorHunan Cancer HospitalRan2018 to 2020Enrolled84ConditionsNon-small Cell Lung CancerArmsAnlotinib Plus Docetaxel, Docetaxel
NCT03726736 phase1 / phase2unknown statusnot on this map

Anlotinib Combined With Docetaxel Versus Docetaxel for Platinum-based Therapy Treated Advanced NSCLC: a Multicentre, Randomised Explorative Trial

TypeinterventionalSponsorYong FangRan2018 to 2020Enrolled97ConditionsNon-small Cell Lung CancerArmsAnlotinib combined Docetaxel, Docetaxel
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xingxiang Pu *Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Jiawei Shou *Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zemin XiaoDepartment of Oncology, The First People's Hospital of Changde City, Changde, China.
Jun ChenTumor Radiochemotherapy Department, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
Maoliang XiaoDepartment of Oncology, Hunan Province Directly Affiliated TCM Hospital, Zhuzhou, China.
Qunyi GuoHematology Oncology, Taizhou Hospital of Zhejiang Province, Taizhou, China.
Zhongxia MaDepartment of Thoracic Oncology Surgery, The First People's Hospital of Chenzhou City, Chenzhou, China.
Wei HongDepartment of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Qianzhi WangDepartment of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Yonghui WangDepartment of Medical Oncology, Thoracic Cancer, Lishui Municipal Central Hospital, Lishui, China.
Jia LiDepartment of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Chuangzhou RaoDepartment of Radiotherapy and Chemotherapy, Ningbo No.2 Hospital, Ningbo, China.
Jie WengDepartment of Oncology, Yueyang Central Hospital, Yueyang, China.
Liqin LuMedical Oncology, Zhejiang Provincial People's Hospital, Hangzhou, China.
Lin WuDepartment of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. wulin-calf@vip.163.com.
Yong FangDepartment of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. fangyong@srrsh.com.

Funding

Beijing Xisike Clinical Oncology Research Foundation Y-2019Genecast-024Hunan Cancer Hospital Climb plan ZX2020005-5Hunan Lung Cancer Clinical Medical Research Center 2023SK4024Hunan Provincial Natural Science Foundation of China 2021JJ30430The science and technology innovation Program of Hunan Province 2021SK51121The science and technology innovation Program of Hunan Province 2023SK4024
6 · The paper itself

Abstract

introductionTherapeutic options for patients with advanced non-small cell lung cancer (NSCLC) after progression on immune checkpoint inhibitors (ICIs) remain a significant challenge. This analysis compared outcomes of anlotinib plus docetaxel versus docetaxel alone in this population using the pooled data from two prospective randomized trials (ALTER-L016; ALTER-L018).

methodsAdult patients with EGFR/ALK/ROS1 wild-type advanced NSCLC progressing on first-line ICIs were eligible. Patients were randomly assigned to anlotinib plus docetaxel or docetaxel alone. The primary endpoint was progression-free survival (PFS). The secondary endpoints were overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety.

resultsSeventy-one patients were included in this pooled analysis (L016, n = 39; L018, n = 32), of whom, 40 received anlotinib plus docetaxel and 31 received docetaxel. The median follow-up of all patients was 27.0 months. The median PFS was longer with anlotinib plus docetaxel than with docetaxel alone (5.4 months [95% CI 5.0-9.3] vs. 2.3 months [95% CI 1.4-2.9]; hazard ratio [HR], 0.34; 95% CI 0.18-0.63; P < 0.001). Both ORR (25.0% vs. 12.9%) and DCR (82.5% vs. 45.2%) were higher in the anlotinib plus docetaxel group than in the docetaxel group. Median OS was 16.2 months (95% CI 8.3-21.3) with anlotinib plus docetaxel versus 13.7 months (95% CI 4.6-22.3) with docetaxel (HR = 0.82; 95% CI 0.47-1.44; P = 0.488). Subsequent ICI therapy was associated with a longer OS. Grade 3 treatment-related adverse events occurred in 32.5% of patients receiving anlotinib plus docetaxel and 6.5% of patients receiving docetaxel.

conclusionAnlotinib plus docetaxel improved PFS but not OS versus docetaxel in patients with advanced NSCLC progressing on ICIs. Larger standardized phase 3 trials are needed to verify these findings.

trial registrationALTER-L016 (ClinicalTrials.gov identifier, NCT03726736). ALTER-L018 (ClinicalTrials.gov identifier, NCT03624309).

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungDocetaxelIndolesLung NeoplasmsQuinolinesAdultAgedFemaleHumansImmunotherapyMaleMiddle AgedProgression-Free SurvivalRandomized Controlled Trials as TopicanlotinibDocetaxelIndolesQuinolinesAnlotinibDocetaxelImmune checkpoint inhibitorsNon-small cell lung cancerProgressing on immunotherapy

Identifiers

PMID40354010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.